Patents by Inventor Robert Chadwick Cummins

Robert Chadwick Cummins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20230265151
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. These compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). These compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: January 21, 2021
    Publication date: August 24, 2023
    Inventors: Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Robert Chadwick CUMMINS, Mohamed Elsayed Hamed ELSAYED, Andrea Renee GEISER, Xianyin LAI, Hongchang QU, Brian Morgan WATSON
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20220048967
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 17, 2022
    Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
  • GIP/GLP1 co-agonist compounds
    Patent number: 11084861
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 10, 2021
    Assignee: Eli Lilly and Company
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai
  • Peptide compound for treatment of severe hypoglycemia
    Patent number: 9695225
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Compound for treatment of severe hypoglycemia
    Patent number: 9688736
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311882
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311883
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311881
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • GIP and GLP-1 co-agonist compounds
    Patent number: 9474780
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: October 25, 2016
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • GIP AND GLP-1 CO-AGONIST COMPOUNDS
    Publication number: 20160199438
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Application
    Filed: January 5, 2016
    Publication date: July 14, 2016
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20080096811
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: April 24, 2008
    Applicant: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez